Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05583188 · ClinicalTrials.gov registry record · Phase 4
Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC
A Phase 4 study, sponsored by Galvanize Therapeutics.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT05583188 is a Phase 4 study that was terminated before completion, run by Galvanize Therapeutics. The registered enrollment target is 5 participants.
The verdict
NCT05583188, a Phase 4 study, was terminated before completion, sponsored by Galvanize Therapeutics.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
A prospective, single-arm, non-randomized, multi-center, open-label study following patients with resectable stage IIB to IIIA non-small cell lung cancer after Pulsed Electric Fields (PEF) ablation who may be candidates for standard of care neoadjuvant use of checkpoint inhibitor (nivolumab) treatment plus platinum doublet chemotherapy.
Interventions
- DEVICE Aliya Pulsed Electric Fields (PEF) ablation
- DRUG Nivolumab plus Platinum Doublet Chemotherapy
- DRUG Standard of care neoadjuvant therapy
- OTHER Surgical Resection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2024-03-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05583188
The ClinicalTrials.gov registry entry for NCT05583188 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galvanize Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Aliya Pulsed Electric Fields (PEF) ablation is the first listed.
NCT05583188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05583188 about?
NCT05583188 is a clinical study titled "Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC". A prospective, single-arm, non-randomized, multi-center, open-label study following patients with resectable stage IIB to IIIA non-small cell lung cancer after Pulsed Electric Fields (PEF) ablation who may be candidates for standard of care neoadjuvant use of checkpoint inhibitor (nivolumab) treatme...
What is the current status of trial NCT05583188?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2023-02-01. Estimated completion is 2024-03-18.
What interventions are being tested in trial NCT05583188?
The interventions under investigation include: Aliya Pulsed Electric Fields (PEF) ablation (DEVICE), Nivolumab plus Platinum Doublet Chemotherapy (DRUG), Standard of care neoadjuvant therapy (DRUG), Surgical Resection (OTHER).
Who is sponsoring clinical trial NCT05583188?
This trial is sponsored by Galvanize Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.